127.00
127.00
Inclusive of all taxes
You Save: 0. Discount 0%
Product is not available
CID-0-RAB DSR Tablet is a combination medication containing Rabeprazole Sodium (20 mg) and Domperidone (30 mg) in a sustained-release/delayed-release formulation. It is used in the treatment of gastroesophageal reflux disease (GERD), chronic dyspepsia, acid reflux, and peptic ulcer disease. The dual-action formulation ensures prolonged suppression of gastric acid along with improved gastrointestinal motility, making it ideal for patients who require long-lasting symptom control. Manufactured under WHO-GMP and ISO-certified standards by BluepillExpress, this product offers consistent quality, patient comfort, and therapeutic efficacy for domestic and international markets.
This product is manufactured under the Dr Precision label, ensuring GMP-compliant quality and precision formulation standards.
CID-0-RAB DSR Tablet is a fixed-dose combination of Rabeprazole Sodium 20 mg (enteric-coated) and Domperidone 30 mg (sustained-release) designed for the effective management of acid-related disorders of the upper gastrointestinal tract. It is commonly prescribed in the treatment of GERD (gastroesophageal reflux disease), peptic ulcer disease, non-ulcer dyspepsia, acid reflux, gastritis, post-meal bloating, and other functional GI disorders involving excess acid and delayed gastric emptying.
Rabeprazole is a proton pump inhibitor (PPI) that irreversibly inhibits the gastric H+/K+ ATPase enzyme located on the surface of parietal cells in the stomach. By blocking this enzyme, Rabeprazole significantly reduces the secretion of hydrochloric acid in the stomach, thereby lowering acidity, healing ulcers, and relieving symptoms such as heartburn, indigestion, and acid regurgitation. Being enteric-coated, Rabeprazole is protected from degradation in the stomach and becomes active only in the small intestine, ensuring maximum efficacy and minimum side effects.
Domperidone is a dopamine D2 receptor antagonist that acts as a gastrointestinal prokinetic agent. It facilitates the movement of food through the digestive tract by enhancing the motility of the stomach and intestines. Domperidone also has antiemetic properties by acting on the chemoreceptor trigger zone (CTZ) in the brain. In the sustained-release form used in CID-0-RAB DSR, Domperidone provides extended prokinetic action over 12 to 24 hours, promoting better gastric emptying and preventing symptoms like bloating, nausea, and a feeling of fullness.
The combination of these two agents in a dual-release formulation offers a comprehensive and long-acting approach to the treatment of functional gastrointestinal disorders. Rabeprazole takes care of the acid production, while Domperidone improves gastric motility and helps relieve discomfort associated with delayed gastric emptying. This makes CID-0-RAB DSR Tablet especially effective in managing patients with chronic or severe acid reflux symptoms that are not adequately controlled with standard PPIs alone.
This formulation is often recommended for:
Gastroesophageal reflux disease (GERD)
Peptic ulcers
Functional dyspepsia
Non-ulcer acid dyspepsia
Gastritis
Bloating and nausea related to delayed gastric emptying
Prevention of NSAID-induced ulcers
